Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIENDS: PCSK9 Inhibitor for Early Neurological Deterioration in Acute Non-cardiogenic Ischemic Stroke
ChiCTR2200059445Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of evolocumab in ischemic stroke (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: early neurological deterioration. Planned start May 2022; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2200059445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059445.